Which statement describes the primary rationale for using the LSB method in place of ABC?

Which statement describes the primary rationale for using the LSB method in place of ABC?

• A. To improve tissue penetration and reduce signal via smaller enzyme-labeled streptavidin molecules
• B. To increase signal by using fluorescent detection
• C. To eliminate biotin-streptavidin interactions altogether
• D. To shorten the protocol by skipping antibody incubation

Answer: (A)

The main idea is that the detection complex size influences how well the signal can reach deeper tissue. The LSB approach uses labeled streptavidin, which is smaller than the avidin–biotin complex used in ABC. Because it’s smaller, it diffuses more readily through tissue, improving penetration and reducing steric hindrance in thicker sections. This can lead to more uniform labeling in deeper areas and help lower nonspecific amplification that can come from using a larger complex. The trade-off is that the overall signal can be somewhat reduced compared with the bulky ABC complex, but the gain is better tissue penetration and cleaner background, which is why this approach is preferred in scenarios where reaching deeper tissue is important. The other ideas don’t fit: the method isn’t about switching to fluorescence detection, it doesn’t eliminate biotin–streptavidin interactions—it's still based on that binding step but with a smaller labeled partner—and it doesn’t skip antibody incubation, so protocol length isn’t the main rationale.

The main idea is that the detection complex size influences how well the signal can reach deeper tissue. The LSB approach uses labeled streptavidin, which is smaller than the avidin–biotin complex used in ABC. Because it’s smaller, it diffuses more readily through tissue, improving penetration and reducing steric hindrance in thicker sections. This can lead to more uniform labeling in deeper areas and help lower nonspecific amplification that can come from using a larger complex. The trade-off is that the overall signal can be somewhat reduced compared with the bulky ABC complex, but the gain is better tissue penetration and cleaner background, which is why this approach is preferred in scenarios where reaching deeper tissue is important.

The other ideas don’t fit: the method isn’t about switching to fluorescence detection, it doesn’t eliminate biotin–streptavidin interactions—it's still based on that binding step but with a smaller labeled partner—and it doesn’t skip antibody incubation, so protocol length isn’t the main rationale.